Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients

NCT04998864 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of the Exablate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with high grade glioma undergoing standard of care therapy.

Conditions

Interventions

DEVICE

Magnetic Resonance guided Focused ultrasound (MRgFUS)

FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.

Sponsors & Collaborators

  • InSightec

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2023-07-27
Completion
2023-10-12

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04998864 on ClinicalTrials.gov